VSTM: Reports Encouraging VS-7375 Data
Verastem Oncology reports encouraging clinical activity and favorable safety profile for VS-7375 in Phase 1/2 clinical study
Verastem Oncology Data From TARGET-D 101 Phase 1/2 Clinical Study Of VS-7375 Shows Encouraging Clinical Activity Including Favorable Safety Profile; Broad Anti-Tumor Activity Observed